Skip to content
Research Article Open access CC BY 4.0

Performance Evaluation: Four Chemiluminescent SARS-Cov-2 Immunoassays and Rapid-Card Test in Mild Disease and Seroprevalence of SARS CoV-2 in Frontline Healthcare Workers

Rasika Setia, Mitu Dogra, Anil Handoo, Gokhula Prasath Thangavel, Ramesh Yadav, Purabi Barman, Raj Kumar Kapoor, Amena Ebadur Rahman

International Blood Research & Reviews · pp. 9–22 · Published 15 May 2021

10.9734/ibrr/2021/v12i330151

Abstract

Introduction: The COVID-19 pandemic raised a host of challenges to modern medicine. Key amongst these were in diagnostics, as most SARS-CoV-2 assays had been rapidly developed and released under emergency-use authorization with limited validation on clinical samples and secondly, an increased risk of COVID-19 infection to healthcare workers (HCW). There are limited inter-assay comparisons to detect SARS-CoV-2 antibodies in cases with milder symptoms of COVID-19, necessary to evaluate whether assays can detect SARS-CoV-2 antibodies in patients with mild infection.  Aim: Therefore this study aimed to evaluate the performance of four chemiluminescence immunoassays and a rapid immunochromatographic assay in 100 rRT-PCR diagnosed-recovered frontline HCW with milder COVID-19 disease and secondly to evaluate the seroprevalence of SARS-CoV-2 infection in the asymptomatic frontline HCW at a multispeciality hospital in Delhi, India. Study Design: Serum and plasma samples were obtained from 100 rRT-PCR diagnosed-recovered frontline HCWs with mild disease working across the hospital, and performance of four common chemiluminescence immunoassays evaluated. Also samples of 505 asymptomatic, frontline HCWs working in hospital, who had not developed or shown any symptoms of COVID-19 infection to date was collected and the seroprevalence of infection was evaluated. Place and Duration of the Study: A study was conducted at BLK Superspeciality Hospital, New Delhi from September to October 2020. Methods: Four chemiluminescence immunoassays [Abbott SARS-CoV-2 IgG (Nucleocapsid), Roche Elecsys® Anti-SARS-CoV-2 Total (Nucleocapsid), Ortho-Clinical Diagnostics: VITROS Anti-SARS-CoV-2 IgG (Spike) and Anti-SARS-CoV-2 Total (Spike)] and a rapid assay [Medsource Ozone Biomedicals] were evaluated in 100 rRT-PCR diagnosed-recovered frontline HCW with mild disease. Also, seroprevalence was studied in 505 asymptomatic, frontline HCW.  Results: At manufacturers' thresholds, overall sensitivity for Abbott was 71%, Roche 96%, Ortho (both total and IgG(S) 99% and rapid card 56%. Seroprevalence in asymptomatic frontline HCW was found to be 17.6%, with positivity being higher in the HCW group not facing patients directly compared to direct patient caregivers (P = 0.0034). Conclusion: Assay performance depends on assay design (total IgM & IgG antibodies versus IgG alone), choice of antigen, and time of sample testing from the onset of disease. In our study, Ortho Vitros total-Ab; IgG (Spike), and Roche Elecsys total-Ab (Nucleocapsid) assays were found to have optimal sensitivity. A seroprevalence study in the frontline HCWs at our institute showed that seroprevalence was higher (17.6%) in HCWs in comparison to the community.

Chemiluminescent assay COVID-19 frontline healthcare workers SARS-CoV-2 antibody seroprevalence

References (25)

  1. 1 A Novel Coronavirus from Patients with Pneumonia in China, 2019 [DOI]
  2. 2 Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019 [DOI]
  3. 3 Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients [DOI]
  4. 4 COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes [DOI]
  5. 5 Risk of COVID-19 in health-care workers in Denmark: an observational cohort study [DOI]
  6. 6 Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison [DOI]
  7. 7 SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden [DOI]
  8. 8 Work-related COVID-19 transmission in six Asian countries/areas: A follow-up study [DOI]
  9. 9 Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers [DOI]
  10. 10 Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area [DOI]
  11. 11 SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey [DOI]
  12. 12 Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2 [DOI]
  13. 13 Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results [DOI]
  14. 14 Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories [DOI]
  15. 15 Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG [DOI]
  16. 16 Prevalence and Clinical Presentation of COVID-19 among Healthcare Workers at a Dedicated Hospital in India
  17. 17 Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples [DOI]
  18. 18 Comparative Clinical Evaluation of the Roche Elecsys and Abbott Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serology Assays for Coronavirus Disease 2019 (COVID-19) [DOI]
  19. 19 Covid-19: Two antibody tests are “highly specific” but vary in sensitivity, evaluations find [DOI]
  20. 20 The impact of sex and age on T cell immunity and ischemic stroke outcomes [DOI]
  21. 21 Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection [DOI]
  22. 22 Evaluation of High-Throughput Serological Tests for SARS-CoV-2 [DOI]
  23. 23 Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India [DOI]
  24. 24 Antibody testing for coronavirus disease 2019: not ready for prime time [DOI]
  25. 25 Seroprevalence of Antibodies to SARS-CoV-2 in Healthcare Workers in Non-epidemic Region: A Hospital Report in Iwate Prefecture, Japan [DOI]

Cited by 3

Persistent Antibody Responses to SARS-CoV-2 Infection in Cancer Patients: A Single-Center Retrospective Observational Study

Amit Agarwal, Saphalta Baghmar, Suhail Qureshi · Indian Journal of Medical and Paediatric Oncology · 2021

Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India

R. Jain, M.V. Mallya, S. Amoncar · Transfusion Clinique et Biologique · 2022

Showing 2 of 3 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

30

Page views

0

PDF downloads

4

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.